IRIS
DE TURSI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.863
EU - Europa 3.061
AS - Asia 2.729
SA - Sud America 542
AF - Africa 52
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 4
Totale 11.264
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.766
SG - Singapore 1.299
CN - Cina 740
IE - Irlanda 672
IT - Italia 616
BR - Brasile 461
SE - Svezia 434
UA - Ucraina 267
DE - Germania 239
FR - Francia 227
GB - Regno Unito 214
VN - Vietnam 203
TR - Turchia 181
IN - India 143
RU - Federazione Russa 96
FI - Finlandia 79
CA - Canada 47
BE - Belgio 44
HK - Hong Kong 44
PL - Polonia 41
AT - Austria 38
MX - Messico 36
JP - Giappone 28
AR - Argentina 25
BD - Bangladesh 22
CZ - Repubblica Ceca 19
NL - Olanda 19
ZA - Sudafrica 19
ES - Italia 17
EC - Ecuador 13
CO - Colombia 12
IQ - Iraq 12
EG - Egitto 11
EU - Europa 11
LT - Lituania 10
ID - Indonesia 9
MA - Marocco 9
PK - Pakistan 8
PY - Paraguay 7
CL - Cile 6
PT - Portogallo 6
RO - Romania 6
UY - Uruguay 6
VE - Venezuela 6
GR - Grecia 5
JO - Giordania 5
KR - Corea 5
PE - Perù 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
AU - Australia 3
ET - Etiopia 3
KE - Kenya 3
NP - Nepal 3
AZ - Azerbaigian 2
CH - Svizzera 2
GT - Guatemala 2
HN - Honduras 2
IL - Israele 2
IR - Iran 2
JM - Giamaica 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CM - Camerun 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
MT - Malta 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
PR - Porto Rico 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 11.264
Salva come PNG Salva come JPEG
Città #
Singapore 974
Chandler 877
Dublin 648
Jacksonville 447
Ashburn 295
Dallas 264
Princeton 262
Beijing 233
Los Angeles 153
The Dalles 130
Nanjing 124
Chieti 118
Izmir 112
Santa Clara 108
Dearborn 105
Wilmington 105
Southend 104
Altamura 100
Ann Arbor 89
New York 89
Munich 74
Pescara 72
Ho Chi Minh City 60
Boardman 57
Cambridge 54
Buffalo 52
Redondo Beach 50
Dong Ket 47
Hong Kong 44
Brussels 43
São Paulo 40
Washington 39
Menlo Park 36
Hanoi 32
Tongling 32
Nanchang 30
Warsaw 29
Rome 26
Tokyo 26
Houston 25
Shenyang 24
Helsinki 23
Nuremberg 23
Boston 22
Frankfurt am Main 22
Council Bluffs 21
Montreal 21
Norwalk 21
Vienna 21
Hefei 20
Brooklyn 19
Falls Church 19
Hebei 19
Milan 19
Woodbridge 19
Chicago 18
Kunming 18
London 18
Atlanta 17
Phoenix 17
Rio de Janeiro 17
Seattle 17
Amsterdam 16
Denver 16
Johannesburg 16
Orem 16
Tianjin 16
Stockholm 14
Ancona 13
Jiaxing 13
Turku 13
Hangzhou 12
Hyderabad 12
Brno 11
Mexico City 11
Poplar 11
Edinburgh 10
Porto Alegre 10
Toronto 10
Cairo 9
Campinas 9
Pune 9
Redwood City 9
San Francisco 9
Belo Horizonte 8
Charlotte 8
Chennai 8
Grevenbroich 8
Kraków 8
Manchester 8
Changchun 7
Curitiba 7
Dhaka 7
Guayaquil 7
New Delhi 7
Shanghai 7
Ankara 6
Brasília 6
Changsha 6
Da Nang 6
Totale 7.019
Salva come PNG Salva come JPEG
Nome #
A multicenter phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary Results 148
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 148
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 147
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 144
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 137
PERITONECTOMIA ED HIPEC NEL TRATTAMENTO DELLA CARCINOSI PERITONEALE: RISULTATI PRELIMINARI DOPO UN ANNO DI ESPERIENZA 135
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 134
New Targets for Therapy in Pancreatic Cancer 134
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 128
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 128
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 125
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 124
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 122
PO-1074 Radiotherapy and immuno-check point inhibitors for brain metastases. A mono-institutional analysis 121
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 120
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 120
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 120
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 119
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 118
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 117
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 116
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 116
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 115
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 114
Cytokine Levels and UVr Sensitivity in HaCaT Cells and Cetuximab Treated Patients. 110
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 110
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 109
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 108
Principali effetti collaterali delle terapie mediche 107
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 107
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 106
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 106
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 105
Speed rate (SR) as a new dynamic index of melanoma behavior 103
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 103
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 103
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 101
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 100
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 100
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 99
Rivaroxaban for cancer-associated cardiac thrombosis 98
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 98
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 98
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 98
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 97
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 97
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 97
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 97
A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results 97
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 97
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 96
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 95
Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study 95
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 94
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 93
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 91
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 91
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 90
null 90
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 86
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study 86
Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study 86
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 86
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study 85
Real world treatment practice in patients with advanced melanoma in the nivolumab era: five novel Italian case reports and a literature review 85
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 84
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 83
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study 83
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 82
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 82
Pretreatment neutrophil-lymphocyte ratio (NLR) predicted overall survival (OS) for metastatic melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) patients who received monotherapy with immune checkpoint inhibitor as ipilimumab, nivolumab and pembrolizumab 82
Epirubicin plus low-dose trastuzumab in HER2 positivemetastatic breast cancer 80
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. 80
Cabazitaxel after Docetaxel in patients with metastatic, castration-resistant, prostate cancer (mCRPC): A prospective, observational study about toxicity profile and quality of life. 80
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 80
Poor risk metastatic renal cell carcinoma (mRCC) patients are not a homogeneous group: a new stratificating model in the era of targeted therapy. 79
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding study 79
Treatment and outcome (s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC) 79
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 79
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 79
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients 78
F05Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 77
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 77
Enzalutamide in real life: Results from a retrospective, multicenter, italian study 76
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. 75
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS) 75
Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure 75
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents 74
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 74
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 74
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 73
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 73
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results 73
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC) 73
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer 71
PO-06 Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 71
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 71
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. 70
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 70
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 67
Totale 9.728
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.213
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.213
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021440 0 0 0 0 0 168 33 24 58 51 30 76
2021/2022803 19 28 14 193 75 26 20 43 51 20 68 246
2022/20232.328 205 323 188 257 166 411 115 216 273 23 103 48
2023/20241.042 63 32 79 34 67 394 177 43 25 35 10 83
2024/20252.335 133 454 303 68 56 125 120 126 256 140 290 264
2025/20262.453 409 202 564 661 544 73 0 0 0 0 0 0
Totale 12.008